Upcoming event

Masterclass on Focal therapy for localised prostate cancer

Home / TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Back

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Neeraj Agarwal,
Arun Azad,
Joan Carles,
Andre P. Fay,
Nobuaki Matsubara,
Daniel Heinrich,
Cezary Szczylik,
Ugo De Giorgi,
Jae Young Joung,
Peter C.C. Fong,
Eric Voog,
Robert J Jones,
Neal D. Shore,
Curtis Dunshee,
Stefanie Zschaebitz,
Xun Lin,
Cynthia G. Healy,
Nicola Di Santo,
Fabian Zohren,
Karim Fizazi

https://meetings.asco.org/abstracts-presentations/216877